All News

Sjogren_syndrome_salivary%20bx%282%29.jpg

Biologic Treatment of Primary Sjogrens with Ianalumab

d Jack Cush, MD

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.

Read Article
IV,arm,intravenous,infusion

BEAT LUPUS - Belimumab after Rituximab in SLE

d Jack Cush, MD

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article
pregnancy,doctor,consult

COVID-19 in Pregnant Rheumatic Women

d Jack Cush, MD

The Global Rheumatology Alliance (GRA) has studied the outcomes of women with rheumatic disease who were pregnant at the time of infection with coronavirus disease 2019 (COVID-19).

Read Article
2021,year

2021 Rheumatology Year in Review

d Jack Cush, MD

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
Single center comparison of pts with MAS vs malignancy assoc. HLH (mHLH) - overall MAS had less hepatomegaly (0 v 25%), double platelet #s (50 v 29Kµ/L), but lower sIL-2R (6814 vs. 27,972.0) and less mortality (22 v 44%, p=0.18). https://t.co/NGIaPTU0yT

Links:

Dr. John Cush RheumNow ( View Tweet)

Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/fYyV75vAWm https://t.co/zOpCbBrzHJ

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast available for download. 2021 Rheumatology Year in Review https://t.co/0Lpo0IUBHp https://t.co/ysdwmQjeaS

Links:

Dr. John Cush RheumNow ( View Tweet)
There were significantly fewer FDA advisory committee meetings in 2021 (n=10), down dramatically from 35 in 2012, 29 in 2018. Nonetheless the FDA did approve 50 new drugs (NDA) in 2021. https://t.co/rSzHkIMEfg

Links:

Dr. John Cush RheumNow ( View Tweet)

Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/GxmgWIbgSo

Links:

Dr. John Cush RheumNow ( View Tweet)

Duloxetine added to usual analgesics failed to improve pain in 132 hip or knee OA pts by WOMAC pain scores: 1) Dulox + usual care vs 2) Usual care showed no diff in pain at 3 mos or 12 mos. https://t.co/9gR2PNVrPl

Links:

Dr. John Cush RheumNow ( View Tweet)

Good (long) open read review of Imaging in NPSLE (CNS lupus); mainly showing there is no SPECIFIC CNS imaging finding for NPSLE. Rather imaging (CT, MRI) done to r/o other pathology. PRES, PML, Vasculopathy, White matter lesions https://t.co/baUp6kjsKr

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of subcutaneous ianalumab in patients with primary Sjögren's syndrome met primary objective, showing dose-related decrease in disease activity (ESSDAI) at week 24: randomised, double-blind, placebo-controlled trial. https://t.co/NqdDWqpX2g https://t.co/PSxSRx28fM

Links:

The Lancet TheLancet ( View Tweet)
My patient measures morning stiffness in his joints by coffee units. Today, it’s 3 ☕️- an equivalent of 1 hour. #rheumatology

TheDaoIndex KDAO2011 ( View Tweet)

In Mouse Model of Lupus, when the gut microbiome of NZM2410 mice colonized w/ SFB, glomerulonephritis worsened & was assoc. w/ incr in TH17, MCP-1 and CXCL1, & more microbial abundance & biodiversity (dysbiosis) https://t.co/bLxrJZKTDZ

Links:

Dr. John Cush RheumNow ( View Tweet)

NICE (UK) has recommended upadacitinib for use in active Psoriatic Arthritis, 15 mg qd +/- MTX, in pts not responding to DMARDS. UPA can now be used in England Wales and Scotland https://t.co/JFxMrgjrUe

Links:

Dr. John Cush RheumNow ( View Tweet)

The global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027. https://t.co/hQTDc0ajdN

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Comorbidities Drive Risk of Severe Outcomes with COVID-19 https://t.co/9GgfvgnMke https://t.co/JGHp0mVPpF

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Study of biologic/ts DMARD switching in 8,398 axial spondyloarthritis pts from 5 Nordic registries showed a low rate of multiple switches (refractory?) over 3 years; ≥3 DMARDs (8%), ≥4 (3%) & ≥ 5 (1%); more w/ women, comorbiditiy & psoriasis https://t.co/tc5D3Bwnnj

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Cosentyx (secukinumab) was FDA approved for use in pediatric psoriatic arthritis & enthesitis-related arthritis, based on results of the ph III JUNIPERA study. Dosing based on weight (SEC 75 mg sc if 15-50kg; SEC 150 mg sc if 50 kg or more) https://t.co/S6mQmwKT1X

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. Read more : https://t.co/OAPdLCxHgy https://t.co/0RnYKeg891

Links:

Dr. John Cush RheumNow ( View Tweet)
×